[go: up one dir, main page]

ECSP003725A - Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina - Google Patents

Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Info

Publication number
ECSP003725A
ECSP003725A ECSP003725A ECSP003725A EC SP003725 A ECSP003725 A EC SP003725A EC SP003725 A ECSP003725 A EC SP003725A EC SP003725 A ECSP003725 A EC SP003725A
Authority
EC
Ecuador
Prior art keywords
tetrahidrotetralina
propilamino
ceto
evil
administration
Prior art date
Application number
Other languages
English (en)
Inventor
David Juergen Wustrow
Lawrence David Wise
Durk Dijkstra
Leonard Theodore Meltzer
Bastiaan Johan Venhuis
Hakan Vilhelm Wikstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP003725 priority Critical patent/ECSP003725A/es
Publication of ECSP003725A publication Critical patent/ECSP003725A/es

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El mal de Parkinson se trata con un compuesto de la fórmula (gráfico), o una sal farmacéuticamente aceptables del mismo.
ECSP003725 2000-10-19 2000-10-19 Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina ECSP003725A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP003725 ECSP003725A (es) 2000-10-19 2000-10-19 Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP003725 ECSP003725A (es) 2000-10-19 2000-10-19 Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Publications (1)

Publication Number Publication Date
ECSP003725A true ECSP003725A (es) 2001-04-23

Family

ID=42041304

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003725 ECSP003725A (es) 2000-10-19 2000-10-19 Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina

Country Status (1)

Country Link
EC (1) ECSP003725A (es)

Similar Documents

Publication Publication Date Title
NO2012015I2 (no) Dapoxetine
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
GB0318447D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
BR0316753A (pt) Método de tratamento para disfunção sexual
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
EA200500859A1 (ru) Хинолинилпирролопиразолы
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AR036137A1 (es) Sales novedosas de derivados anticonvulsivos
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
DE60128100D1 (de) Analgetisches arzneimittel
HK1058515A1 (en) Use of pamoic acid for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates.
SE0101082D0 (sv) Novel use
ECSP014079A (es) Derivados de sulfonamida
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina
AR035406A1 (es) Procedimiento de preparacion de eletriptan
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.
ECSP014078A (es) Derivados de sulfonamida
SV2001000202A (es) Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.